Statins raise HbA1c (a three-month average of blood sugar) by roughly 0.04% to 0.12%, depending on the specific drug and dose. For most people, that translates to a barely noticeable bump in fasting glucose. But the picture gets more complicated at higher doses and for people already on the edge of diabetes, where statins can tip the scales.
The Average Blood Sugar Increase
Multiple large analyses have tried to pin down the exact effect. A meta-analysis of 26 statin trials with over 3,200 participants found that the mean HbA1c change was just 0.04%, which the researchers described as having “no remarkable influence.” A separate analysis of nine placebo-controlled trials reported a slightly larger shift: HbA1c levels were 0.12% higher in statin users after an average follow-up of 3.6 years. A third network meta-analysis of 23 trials landed in between, at 0.11%.
To put those numbers in context, an HbA1c of 5.7% versus 5.8% is the kind of difference we’re talking about. The 2026 ACC/AHA lipid guidelines call this increase “small” and “clinically insignificant,” estimating 0.06% to 0.08% in patients who already have diabetes. You wouldn’t feel this change, and it wouldn’t meaningfully shift your diabetes management on its own.
Dose Matters More Than Most People Realize
The blood sugar effect is not the same across all statin prescriptions. Low-to-moderate intensity statin therapy raises the risk of a new diabetes diagnosis by about 10% compared to placebo. High-intensity statin therapy, the kind prescribed after a heart attack or for very high cardiovascular risk, raises that risk by 36%.
The raw numbers tell the story more clearly. In trials tracking patients for about 4.4 years, 5.56% of people on low-to-moderate dose statins developed diabetes compared with 5.14% on placebo. That’s a tiny absolute difference: you’d need to treat 240 people to cause one extra case of diabetes. For high-intensity statins, the gap was wider: 19.04% versus 14.27%, meaning roughly one extra diabetes diagnosis for every 21 people treated. That’s a real, measurable effect.
For perspective, those same high-intensity statins prevent one heart attack for every 77 people treated. So the diabetes risk is about 3.7 times more common than the heart attack prevention benefit on a per-person basis. That trade-off still favors statin use for people at high cardiovascular risk, but it’s worth understanding.
Not All Statins Affect Blood Sugar Equally
Atorvastatin appears to drive more of the blood sugar effect than other statins. In the meta-analysis that found a 0.12% HbA1c increase overall, most of that signal came from atorvastatin specifically. The same pattern showed up in studies looking at patients with type 2 diabetes, where atorvastatin was associated with a greater HbA1c rise than other options.
Pravastatin and pitavastatin have generally shown smaller effects on glucose metabolism in clinical trials. If blood sugar is a particular concern for you, this is a conversation worth having with your prescriber, since switching to a different statin can sometimes preserve the cholesterol-lowering benefit with less glucose impact.
Why Statins Raise Blood Sugar
Statins work by blocking an enzyme your liver uses to make cholesterol. That same enzyme sits at the top of a biochemical chain reaction that affects several other processes in your body, and some of those processes are involved in blood sugar regulation. The effect isn’t a single simple pathway. It’s several overlapping ones.
First, statins can impair the insulin-producing cells in your pancreas. By disrupting cholesterol metabolism, they cause cholesterol to accumulate inside these cells, which interferes with the calcium signaling those cells need to release insulin when blood sugar rises. In lab studies, one statin cut glucose-triggered insulin release by 50% in isolated pancreatic cells.
Second, statins can make your muscles and fat tissue less responsive to insulin. They appear to interfere with key signaling molecules that cells use to absorb glucose from the bloodstream. High concentrations of simvastatin, for example, reduced glucose uptake in fat cells in laboratory experiments.
Third, statins can ramp up glucose production in the liver. Research shows they increase the activity of genes responsible for making new glucose, essentially telling the liver to release more sugar into the bloodstream even when it doesn’t need to. This effect appears to be triggered through a cellular recycling process called autophagy.
These mechanisms work in combination, which is why the glucose effect scales with dose. Higher statin concentrations mean more disruption across all three pathways simultaneously.
Who Is Most Likely to See a Blood Sugar Increase
The glucose effect doesn’t hit everyone equally. The 2026 ACC/AHA guidelines specifically identify several predisposing risk factors: a BMI of 30 or above, fasting blood glucose already at 100 mg/dL or higher, metabolic syndrome, or an HbA1c between 6.0% and 6.4%. If you have one or more of these, you’re more likely to see your blood sugar nudge upward on a statin, and more likely to cross the diagnostic threshold for type 2 diabetes.
This is an important distinction. Statins don’t cause diabetes out of nowhere in metabolically healthy people. What they do is accelerate the timeline for people who were already heading in that direction. If your fasting glucose is 105 and your HbA1c is 6.3%, a statin might push you past the 6.5% line that defines diabetes a year or two sooner than it would have happened otherwise.
The guidelines recommend that prescribers discuss this possibility before starting statin therapy in people with these risk factors. They also emphasize that even if a statin does contribute to a diabetes diagnosis, stopping the statin is not the recommended response. The cardiovascular benefits of statins have been demonstrated even in people who develop diabetes while taking them, and the heart protection outweighs the metabolic cost in the populations where statins are prescribed.
What This Means in Practice
If you’re taking a statin and your blood sugar has crept up slightly, the statin is a plausible contributor, but the effect is modest for most people. An HbA1c increase of 0.1% or so is real but small. The lifestyle factors that influence blood sugar, including diet, exercise, sleep, and body weight, have a much larger impact than the statin effect and remain the most effective levers you can pull.
If you’re on a high-intensity statin and have prediabetes risk factors, periodic blood sugar monitoring makes sense. The combination of high-dose treatment and existing metabolic risk is where the meaningful diabetes risk concentrates. For people on moderate doses with normal baseline glucose, the blood sugar effect is unlikely to change anything about your health trajectory.